US 12,268,783 B2
Platform drug delivery system utilizing crystal engineering and theanine dissolution
Harry G. Brittain, Milford, NJ (US); and Philip V. Felice, Smithtown, NY (US)
Assigned to THEAPRIN PHARMACEUTICALS, INC., Hauppauge, NY (US)
Filed by THEAPRIN PHARMACEUTICALS, INC., Hauppauge, NJ (US)
Filed on Feb. 24, 2021, as Appl. No. 17/184,229.
Application 17/184,229 is a continuation of application No. 15/556,977, abandoned, previously published as PCT/US2016/020054, filed on Feb. 29, 2016.
Application 15/556,977 is a continuation of application No. 14/642,191, filed on Mar. 9, 2015, granted, now 9,603,937.
Prior Publication US 2021/0177758 A1, Jun. 17, 2021
Int. Cl. A61K 31/192 (2006.01); A61K 9/14 (2006.01); A61K 31/13 (2006.01); A61K 31/137 (2006.01); A61K 31/198 (2006.01); A61K 31/277 (2006.01); A61K 31/34 (2006.01); A61K 31/4045 (2006.01); A61K 31/4164 (2006.01); A61K 31/4196 (2006.01); A61K 31/426 (2006.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/445 (2006.01); A61K 31/4453 (2006.01); A61K 31/4709 (2006.01); A61K 31/4745 (2006.01); A61K 31/48 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/522 (2006.01); A61K 31/536 (2006.01); A61K 31/545 (2006.01); A61K 31/546 (2006.01); A61K 31/549 (2006.01); A61K 31/573 (2006.01); A61K 31/603 (2006.01); A61K 31/635 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7072 (2006.01); A61K 38/12 (2006.01); A61K 47/26 (2006.01); A61P 31/00 (2006.01); C07C 57/30 (2006.01); C07C 59/105 (2006.01); C07C 69/157 (2006.01); C07C 211/38 (2006.01); C07C 215/58 (2006.01); C07C 229/36 (2006.01); C07C 255/41 (2006.01); C07D 209/14 (2006.01); C07D 209/24 (2006.01); C07D 211/22 (2006.01); C07D 215/22 (2006.01); C07D 233/94 (2006.01); C07D 249/08 (2006.01); C07D 261/16 (2006.01); C07D 265/18 (2006.01); C07D 277/56 (2006.01); C07D 285/28 (2006.01); C07D 307/52 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 457/04 (2006.01); C07D 457/06 (2006.01); C07D 473/18 (2006.01); C07D 473/30 (2006.01); C07D 491/22 (2006.01); C07D 499/00 (2006.01); C07D 499/24 (2006.01); C07D 501/22 (2006.01); C07D 519/00 (2006.01); C07D 519/02 (2006.01); C07H 15/252 (2006.01); C07H 17/08 (2006.01); C07H 19/06 (2006.01); C07K 7/08 (2006.01); C07J 5/00 (2006.01)
CPC A61K 9/145 (2013.01) [A61K 31/13 (2013.01); A61K 31/137 (2013.01); A61K 31/192 (2013.01); A61K 31/198 (2013.01); A61K 31/277 (2013.01); A61K 31/34 (2013.01); A61K 31/4045 (2013.01); A61K 31/4164 (2013.01); A61K 31/4196 (2013.01); A61K 31/426 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/445 (2013.01); A61K 31/4453 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61K 31/48 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/522 (2013.01); A61K 31/536 (2013.01); A61K 31/545 (2013.01); A61K 31/546 (2013.01); A61K 31/549 (2013.01); A61K 31/573 (2013.01); A61K 31/603 (2013.01); A61K 31/635 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7072 (2013.01); A61K 38/12 (2013.01); A61K 47/26 (2013.01); A61P 31/00 (2018.01); C07C 57/30 (2013.01); C07C 59/105 (2013.01); C07C 69/157 (2013.01); C07C 211/38 (2013.01); C07C 215/58 (2013.01); C07C 229/36 (2013.01); C07C 255/41 (2013.01); C07D 209/14 (2013.01); C07D 209/24 (2013.01); C07D 211/22 (2013.01); C07D 215/22 (2013.01); C07D 233/94 (2013.01); C07D 249/08 (2013.01); C07D 261/16 (2013.01); C07D 265/18 (2013.01); C07D 277/56 (2013.01); C07D 285/28 (2013.01); C07D 307/52 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 457/04 (2013.01); C07D 457/06 (2013.01); C07D 473/18 (2013.01); C07D 473/30 (2013.01); C07D 491/22 (2013.01); C07D 499/00 (2013.01); C07D 499/24 (2013.01); C07D 501/22 (2013.01); C07D 519/00 (2013.01); C07D 519/02 (2013.01); C07H 15/252 (2013.01); C07H 17/08 (2013.01); C07H 19/06 (2013.01); C07K 7/08 (2013.01); A61K 2300/00 (2013.01); C07B 2200/13 (2013.01); C07C 2603/74 (2017.05); C07J 5/0053 (2013.01); Y02A 50/30 (2018.01)] 4 Claims
 
1. A cocrystal composition comprising L-theanine; and
R-Ibuprofen,
wherein the cocrystal is characterized by an X-ray powder diffraction pattern with peaks (2θ) at 13.1±0.2 degrees 2θ, 17.5±0.2 degrees 2θ, 21.9±0.2 degrees 2θ, and 26.3±0.2 degrees 2θ.